Collas Crill advises Curaleaf on acquisition of EMMAC Life Sciences Limited

Collas Crill has advised Curaleaf on its successful acquisition of EMMAC Life Sciences Limited ('EMMAC') at an implied post money valuation of $413m. EMMAC is Europe's largest vertically integrated independent medicinal cannabis company. Collas Crill's role included advising on the establishment in Guernsey of Curaleaf International Holdings Limited ('Curaleaf International') to hold the EMMAC investment and further its European expansion.

Curaleaf International already has an operational presence in European Union countries that are enacting new medical cannabis access schemes. The company intends to substantially increase its cultivation capacity in 2021 to facilitate anticipated growth through increased access to the use of cannabis across major European and export markets.

Boris Jordan, Executive Chairman of Curaleaf, said: 'The successful completion of our acquisition of EMMAC, and the formation of our new Curaleaf International business, marks a transformational launching point for our entrance into the European cannabis market. Building on our market leading position in the U.S., this transaction establishes Curaleaf as the global, pure play, cannabis market leader by revenue and geographic reach.'

Group Partner Paul Wilkes and Senior Associate Gareth Morgan led Collas Crill's advisory team.

Paul said: 'It was a pleasure to work with the Curaleaf and broader transaction team to get this transaction over the line, notwithstanding a challenging timeline and some complex elements. Well done to all and really proud of the entire Collas Crill team, in particular Gareth's coordination and leadership as we neared the finish line.'

To find out more about the acquisition, visit Curaleaf International's website.

For more information about Collas Crill's M&A services, click here.